Journal
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
Volume 18, Issue 1, Pages -Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ijnp/pyu007
Keywords
chemogenetics; GPCRs; GsD; hM3Dq; hM4Di
Funding
- NARSAD Distinguished Investigator grant
- NIMH [U19MH82441]
Ask authors/readers for more resources
Recently, we created a family of engineered G protein-coupled receptors (GPCRs) called DREADD (designer receptors exclusively activated by designer drugs) which can precisely control three major GPCR signaling pathways (Gq, Gi, and Gs). DREADD technology has been successfully applied in a variety of in vivo studies to control GPCR signaling, and here we describe recent advances of DREADD technology and discuss its potential application in drug discovery, gene therapy, and tissue engineering.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available